Participation in this year’s survey was similar to previous years with 5,235 people taking part and returning records for 15,433 horses. Most horses were kept in livery or a private yard and used for leisure and hacking and the majority within the age range of 5 to 10 years.
A broad variety of breeds were represented, including natives, thoroughbred types and warmbloods.
59% of horses were recorded as healthy and 41% with one or more health problems, compared to 62% and 38% respectively in 2016.
The top five disease syndromes recorded this year were:
Of the 5.5% of horses recorded with back problems 26% were also showing signs of lameness. While the details of the results do not confirm that the two are necessarily connected, these findings reflect the outcome of recent studies conducted by Dr Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust.
Sue said: "It is a common observation that horses with lameness stiffen the back as a protective mechanism and develop muscle pain which may be misinterpreted as a primary back problem. We have shown objectively that abolition of lameness by diagnostic analgesia results in an immediate increase in range of motion of the back. The current data supports this close relationship between lameness and back pain."
All existing BEVA members will have their membership automatically extended until 30 June 2020. The association is also inviting vets and vet nurses who are not already BEVA members to join as online members free of charge until 30 June 2020.
BEVA President Tim Mair said: “In this extraordinary time of global crisis our profession, as with many industries, is under immense pressure. By offering free membership we are giving equine vets easy access to a wealth of supportive resources and online CPD to help them through these dark times.”
BEVA membership includes:
The association is also looking at other ways to support the profession, which has included making all BEVA Congress 2019 webinars available to members via the BEVA online learning platform.
To sign up from Monday 30 March 2020 visit: https://www.beva.org.uk/Join-BEVA
This year's National Equine Health Survey, conducted by the Blue Cross and supported by Zoetis, has revealed that 20% of owners who claimed to have treated for encysted small redworm (ESRW) used a wormer that was not indicated to treat the parasite.
3,669 horse owners took part in the survey, which was conducted in May 2014. It contained 25 questions on general horse health, care and management and was validated by Professor Josh Slater at the Royal Veterinary College.
Zoetis says the findings suggest that horses are being left at serious risk (untreated, encysted small redworm may develop and emerge en masse from the gut wall, causing diarrhoea and colic with a mortality rate of up to 50%1).
The company is now running an encysted small redworm awareness campaign at www.esrw.co.uk, where owners can test their knowledge before discussing the best treatment options with their vet.
References
1. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242
At 9.00am on Thursday and 1.45pm on Friday, Dr Sam Taylor, Feline Specialist and academy lead at the International Society of Feline Medicine (ISFM), will present ‘feline pawsative’, a talk about about cat inappetence and the remedy offered by Mirataz.
At 11.20am on Thursday and 9.00am on Friday, Matt Gurney, clinical director at Anderson Moores will be sharing the latest developments in sedation in dogs including Zenalpha.
At 12.30pm on Thursday and 12.35pm on Friday, Andrew Waller (pictured right), chief scientific officer at Intervacc AB, will be discussing how to rein in the impact of strangles using Dechra’s new protein-based vaccine, Strangvac.
The CPD sessions are first come, first served, and Dechra says it expects the presentations to be well-attended, so it could be worth getting there a little early, although probably no need to pitch a tent outside the night before.
Bruce Bladon will describe current antibiotic use in equine practice, Victoria South will consider the use of Highest Priority Critically Important Antimicrobials, and Bettina Dunkel will describe strategies to reduce antimicrobial use.
The webinar is free for both members and non-members.
To register, visit: https://us02web.zoom.us/webinar/register/7016678281618/WN__XNTbcxoQ2K1mXUGOIVL_g
Photo: Safia Barakzai, Equine Surgeon
Intervet/Schering-Plough Animal Health has announced that it is to sponsor the Equine Business Management Strategies (EBMS) program, a targeted business education program developed for equine veterinary surgeons and practice professionals.
According the company, this 5-day course has proven very successful in the United States. It had its European kick-off in Amsterdam on August 22, 2010, where a group of almost forty equine practitioners from North America and Europe gathered to discuss and learn how to apply business principles in their day-to-day work. The program was chaired by Dr. Joop Loomans, an equine veterinary surgeon responsible for equine business management education at the Department of Equine Sciences of the Veterinary Faculty of Utrecht University (The Netherlands).
Course participants worked with international specialists on strategic planning, benchmarking, branding and change management to create strategic plans to implement at their practices, and to share their knowledge, experience and ideas.
Intervet/Schering Plough says the launch of Equine Business Management Strategies program exceeded expectations of participants, sponsor and organizers. The chance to look at the day-to-day practice from a different angle and to learn about things like benchmarking exercises, revenue analysis and branding was highly appreciated. Participant Jeremy Mantell from Liphook Equine Hospital in the UK said: "The EBMS has given me a clearer understanding of what I need to change and develop in my practice."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering-Plough Animal Health said: "We believe that running an equine practice is not based solely on technical and scientific skills but also on effective practice management. That is why our company has decided to support this initiative. Intervet/Schering-Plough Animal Health also continues its custom of providing not only innovating products, but also new, value-added services to strengthen its bond with veterinarians."
This year’s Horse Health Week, which ran at the end of September, focused on the small things that can be done to help keep Britain’s horses happy and healthy. Equine practices were encouraged to get involved and engage with their clients throughout the week with the support of a toolkit that offered both off and online communication materials.
The toolkit included a social media campaign for practices to run called #BonVoyageBuzz. Horse owners were invited to send 'Buzz' around the (virtual) world by sharing and tagging on Facebook. By the last count, he'd reached Denmark, the U.S., Canada and Saudi Arabia. The final part of Horse Health Week was a survey that gave the views of horse owners on preventative healthcare.
MSD says the week was welcomed and supported by a number of equine vet practices which reported that the campaign generated high levels of engagement from horse owners.
Peter Young, Equine Business Manager said: "Horse Health Week was created to help practices promote their businesses and educate and promote the benefits of preventative healthcare, so we are delighted that we’ve had such a good uptake of the resources we provided this year. A number of equine practices uploaded the daily animations we created to help encourage maximimum engagement. Some also reported the animations and posters being mentioned at yard appointments so, together with equine vet practices, we’ve successfully helped raise awareness and are eduating horse owners."
If you would like to provide feedback speak to your MSD Animal Health Equine Account Manager. For further details, visit: www.healthyhorses.co.uk/horse-week.
81% of equine worming strategies are not effective in fight against resistance, because owners are not conducting an adequate level of faecal egg counts (FEC), according to a survey carried out by Countrywide, the supplier of equestrian products.
The company surveyed nearly 1,000 horse owners in collaboration with Westgate Laboratories, Norbrook and BW Equine Vets and found that 47% have never conducted an FEC test.
When asked about their current approach to worming, 59% of respondents said they worm at set times of the year with only 31% conducting regular FEC tests.
Mark Hawkins, SQP at Countrywide, said: "With worms becoming resistant to some worming drugs, simply dosing all horses with routine wormers is not adequate. A targeted approach, which considers each horse as an individual, is needed."
Gillian Booth owner at Westgate Laboratories said: "The results show that the majority of horse owners are not updating their worming practice to match the increase in resistance and improvement in testing technology. Previous worming practices have led to the resistance problems we now have so it is vital that there is change."
The survey found that veterinary surgeons and in store advisors are vital to promote change - 65% of respondents actively seek advice from their vet and Suitably Qualified Person (SQP) for worming and general health care.
Mark added: “A huge 99% of people worm their horse at least once a year; despite this 38% of horse owners do not know an accurate weight of their horse. Considering inaccurate dosing plays a large role with the increase in resistance this figure is very concerning. If you do need to treat, accurate dosing is essential.”
The survey found that 86% of respondents had wormed for tapeworm, making it the most wormed for parasite. Despite this, only 6% of horse owners had conducted a saliva test for tapeworm, and only 8% had conducted the more established ELISA blood test through their vet to prove the need for this worming dose.
For a full breakdown of the survey results, visit: www.countrywidefarmers.co.uk/wormingsurvey.
Three bursaries are available - two in ruminant and one in companion animal research, each worth up to £4,000.
Annabelle Mohring, Veterinary Advisor at MSD Animal Health said: "We appreciate that the last 18 months have been challenging for many veterinary surgeons and adding new research to this may not be considered a priority. But with the pace of change rapidly increasing, improving business skills and scientific knowledge will become more important than ever for the profession.
"Research forms the foundation of the industry and being awarded a bursary has proved to be a career-changing experience for some participants. We're now welcoming applications as part of our investment in the veterinary community."
Each project should be completed within one to two years and the veterinary surgeon proposals will be judged by objective third party university academics to ensure independent assessment.
The deadline for the MSD Animal Health Veterinary Surgeon Research Bursaries is 30th November 2021.
For further information, visit: www.msdahresearchbursary.co.uk.
Photo: Hattie Barnes who was awarded the 2020 Veterinary Surgeon Bursary in the companion animal sector. She was awarded £4,000 for her analytical, cadaver-based study to investigate different draping protocols in elective orthopaedic surgery. Hattie is currently undertaking a 3-year residency in Equine Surgery at the University of Liverpool.
VetSurgeon member Viki Edmondson MRCVS is taking part in a drive to help 13-year-old Octavia Woodward, who was born with spinal muscular atrophy (SMA), raise £100,000 to help The SMA Trust.
Viki, a well-known vet in the carriage driving world, will be joining Octavia on 'Octavia's Mad Marathon', a five-day, 110 mile carriage drive from Windsor to Wincanton.
Octavia will be driving her pony, Diddy, with her mother Henrietta as co-driver. Meanwhile, Viki will be driving a pair of Gelderlander horses. They'll be leaving the main ring at the Royal Windsor Horse Show with a support crew at 3:30pm on 13th May.
Viki graduated from Bristol Veterinary School in 1993. Since 2001 she has run her own equine practice plus a small animal surgery from the Newdigate, Surrey farm she shares with husband Peter. Viki has known Octavia since she was born and it was Viki who paired up Diddy with Octavia and encouraged her to progress from walking round the roads to the excitement of "off-roading". Viki will be providing support and encouragement to Octavia during the trip - of course with any veterinary help being close by.
To support Viki and Octavia, visit: http://www.justgiving.com/vikithevet
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.
The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.
Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.
Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.
Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.
CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/
Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial
Reference M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x
Boehringer Ingelheim has announced that its 'Talk About Laminitis' campaign will run from Mid March until the end of June.
Last year, the initiative saw over 9000 horses and ponies tested for PPID through its free ACTH test scheme. This year, to build on this success and support the testing of even more animals, the company has announced a high impact, co-ordinated campaign to drive awareness that up to 90% of laminitis cases may have an underlying endocrine cause1,2.
Once again, Boehringer is urging veterinary surgeons to carry out free ACTH blood tests on laminitic or foot-sore horses as part of the campaign, which is backed by Redwings, The British Horse Society and World Horse Welfare.
Professor Andy Durham from the Liphook Equine Hospital, where the ACTH tests are performed, said: "We are learning so much from these tests. For example, we are now recognising PPID routinely in laminitic horses and ponies as young as 10 years old, and in the spring when we might expect to see more EMS cases, where veterinary surgeons have also tested for PPID we are seeing both abnormally elevated ACTH and insulin. Unless the PPID is addressed, horses will continue to be at risk of painful recurrent laminitic episodes which is a significant welfare issue to the horse and extremely frustrating for owners."
To participate in the scheme, veterinary surgeons and horse owners can download ACTH blood test vouchers from www.talkaboutlaminitis.co.uk. Attach the voucher to the ACTH sample submission form and the ACTH laboratory fees will not be charged.
Lee Hackett from The British Horse Society said: "Without the 'Talk About Laminitis' initiative and the support of Boehringer Ingelheim, literally thousands of horses may not be receiving the appropriate treatment and management for their laminitis to help prevent recurrence. We hope as many veterinary surgeons as possible get involved this year to continue this welfare success."
To ensure that horse owners are fully aware of the initiative, a PR and advertising campaign in the equine consumer media will start in March. The ad campaign includes an infomercial on Horse & Country TV (SKY Channel 280), with viewer numbers in excess of 450,000 per month.
There will also be a live online broadcast for horse owners on endocrinopathic laminitis presented by David Rendle BVSc MVM CertEM(IntMed) DipECEIM MRCVS, from the Liphook Equine Hospital in Hampshire. The one-hour webinar, which takes place at 8.00pm on Wednesday 10 April, will educate horse owners on how the veterinary profession's understanding of this debilitating and devastating disease has been completely revolutionised over the past five years. It will be followed by an interactive Q&A session when viewers will be able to pose questions for David to answer.
David said: "As our knowledge of the two hormonal diseases responsible for the majority of cases of laminitis improves, veterinary surgeons can offer their clients more comprehensive advice on treatment options to prevent laminitis. For many owners who have struggled with this condition, this is an absolute revelation and has enormous welfare benefits".
Horse owners can register to view the online programme by visiting www.talkaboutlaminitis.co.uk.
To ensure that veterinary surgeons are versed in the most up to date research available, Boehringer Ingelheim will also be hosting a webinar for veterinary professionals at 8.00pm on Wednesday 13th March, presented by Professor Andy Durham BSc BVSc CertEP DEIM DipECEIM MRCVS. The online seminar, 'The laminitis revolution.... An update on our understanding of endocrinopathic causes of laminitis', will entitle the viewer to a downloadable certificate for one hour of CPD. To register, visit www.bi-academy.co.uk. Places are limited, so register early to avoid disappointment. The webinar will also be available to view after the event on demand.
For further information on how you can promote 'Talk About Laminitis' in your practice contact your Boehringer Ingelheim Territory Manager or call 01344 746959
1. Karikoski et al. (2011). The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital. Domestic Animal Endocrinology 41 111-117
2. Donaldson et al. (2004). Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc;224:1123-1127.
BEVA Congress 2021 will now take place from September 4th-7th 2021.
The decision to cancel Congress 2020 was taken by BEVA Council and the Congress programme committee because of the unpredictable circumstances of the coronavirus pandemic.
Tim Mair, President of BEVA said: “The overriding factor in our decision-making process was to protect everyone attending Congress. We are chartering unknown territory at the moment and the additional planning requirements needed to run a large event like BEVA Congress with social distancing measures in place will take time.
“We intend for September 2021 to mark an exciting, fresh start for the profession following the harrowing experiences of 2020. It should be safe for our international speakers and delegates to attend by then, getting us all back on track with networking and world-class CPD to inspire us for the new post Covid-19 world.”
Tickets for BEVA Congress 2021 will be available later this year, more information from: www.bevacongress.org.
The new Mars Equestrian Veterinary Research Scholar Programme offers the opportunity to conduct research alongside some internationally-renowned experts in equine health and veterinary welfare while pursuing two advanced credentials: the Graduate Certificate in Animal Welfare and Behavior at Penn Vet during year one, followed by the Master of Research (MRes) program at the RVC in year two.
The RVC says the new format offers an exclusive opportunity for the candidate to refine their critical research skills and expand animal welfare knowledge while learning on location at both the RVC in England and Penn Vet’s New Bolton Center in Kennett Square, Pennsylvania, United States.
The RVC’s MRes programme gives students the chance to develop into scientists who can work well across interdisciplinary teams, tackling problems of practical relevance to veterinary and medical science. Many of the courses’ graduates go on to work in some of the world’s leading scientific research institutes, as well as within industry and government.
Professor Richard Bomphrey, Interim Vice Principal for Research at the RVC said: “I am delighted that the RVC is able to support this new transatlantic initiative for veterinary graduates following a generous donation from Mars Equestrian. It strengthens the ties between the RVC, the University of Pennsylvania and Mars Equestrian while providing an outstanding training and research opportunity. We look forward to welcoming the successful scholar and helping them to make an impact in equine research."
The Veterinary Research Scholar program is open to interested UK, US and international candidates holding a veterinary degree (DVM/VMD/BVSc or equivalent). The chosen candidate will receive an annual stipend and tuition as well as travel expenses.
The programme will commence in September 2021 in the United States before moving to the UK in October 2022 until its conclusion in September 2023.
The deadline to submit applications for consideration is 30th June 2021 or until an acceptable candidate is identified.
Applications should be sent to the Penn Vet’s Dr. Kyla Ortved atkortved@vet.upenn.edu.
Zoetis Business Consulting has released figures showing that Profit Solver, its financial analysis tool, has delivered an average EBITDA (earnings before interest, taxes, depreciation and amortization) growth of 36% for the 28 UK practices that have used the new service since its launch.
Profit Solver was first launched in the USA, where the company says more than 300 practices have now benefited from the service.
Zoetis says that traditionally, veterinary practices have set their prices by simply adding a set mark-up, without knowing which services make a profit or loss and without understanding exactly how overall practice profit is being generated.
Profit Solver instead uses the practice’s own data to calculate the exact cost for the 130 most commonly performed veterinary services, representing 90% of the revenue generated by the practice. It then combines labour, inventory and equipment costs with time-and-motion studies for each service, and assesses the variance between cost and price to reveal profit or loss.
By using a collection of cost data, which staff perform which part of the procedure, how long the procedure takes and what equipment and materials are used, Profit Solver calculates the correct pricing to both cover costs and deliver a pre-determined profit margin.
Implementing Profit Solver is done with a Zoetis business consultant who guides the practice through the process, from data collection to examining the time-and-motion studies. They discuss the level of profitability the practice needs to deliver and help analyse prices to achieve this goal whilst preserving the price-point of highly competitive services and covering all the practice’s costs.
Ian Camm, Group Director of B&W Equine Vets in Gloucestershire heard about Profit Solver from a vet in a neighbouring practice who was impressed with how it had helped his business. Ian discussed Profit Solver with his Zoetis account manager and booked an appointment with Zoetis Business Consultant Anthea Pike who has helped him implement the software across B&W Equine Group.
He said: "Initially I was concerned that Profit Solver would suggest we put prices up where we felt that we would not be able to - people shop around for their veterinary services these days and many services are very price sensitive. The first stage in the process addressed this by looking at our figures, calculating the cost price for each procedure and then, by comparing with our fees charged, identified where we were losing money. The big question was whether we would be comfortable to increase our fees on loss-making procedures. The beauty of the system was that by looking at a large number of procedures which were done frequently, very small increases in fee would total to a significant improvement in the bottom line.
"The software has made us recognise where the real costs are and how to address these areas accordingly, for example we have identified that current stud packages are not profitable. One of the problems in arriving at true costs is the difficulty in accurately allocating time to various procedures when several different vets are involved or an expensive scanner is used, which can have a significant impact on the results. It’s early days, but I can already see the difference that Profit Solver could make to our bottom line and wouldn’t hesitate to recommend it providing the practice is prepared to make changes in light of the results. We are looking at improving our bottom line by a six figure sum over a 12 month period with what we hope, will be hardly noticeable price rises.”
For further information visit www.zoetis.co.uk/businessconsulting.
Despite being a common disease, CVS says very little research has been undertaken into EPD in the UK.
In addition, numerous different treatments are currently used for EPD, for which there is not always robust scientific evidence.
The CVS study, which started in 2022 and will continue till early 2024, involves 20 practices.
Samples have been collected from over 70 cases from horses that have been diagnosed by EPD throughout the UK.
Full blood profiles have been assessed, in addition to bacterial culture analysis of the lesions, PCR analysis for dermatophytes (ringworm fungi), microscopy for ectoparasites (mites) and skin cytology.
An owner questionnaire has also been completed to gather information on EDP management.
Each horse’s lesions have been graded and descriptive data relating to the lesions were recorded.
Data collection is now complete and a team of researchers, led by vet Manuela Diaz Ramos, has started analysing the data.
A full report on the findings, along with treatment and management recommendations, is expected to be presented at a scientific conference later this year.
WebLeC has launched a monthly online equine CPD service.
One hour live interactive sessions will take place every third Thursday at 7:30 pm. A single meeting costs £30 plus VAT, or savings can be made by taking out a flexible subscription that allows the user to choose any 12 meetings for the cost of 10 over a period of up to 24 months.
The next meeting is on 22nd September and is entitled: Colic Decision making: When to wake up the surgeon and what pain control to use. The presenter is Debra Archer form the University of Liverpool. Further details and registration links can be found at: http://www.ledstonequine.co.uk/weblec_lectures/colic.html
In addition, a recording of WebLeC's 6th meeting, which was held in partnership with BEVA and the VDS and dealt with the new guidelines and forms for pre-purchase examinations of horses, is now available to view free online at: www.bitly.com/weblecbevaPPE. Use the password: b3va to get access, and you will receive a CPD certificate if you fill in the registration form.
WebLeC has also been asked to host BEVA's online CPD and will be announcing further details of their meetings soon.
BCF Technology has launched a competition to win a top of the range digital radiography system from its Cuattro range for 6 months.
To enter the competition, you need to record a short video (up to 2 minutes) explaining how the DR system would transform your imaging function. BCF is asking entrants to be as creative as possible as the voting will be open to the public. The company will pick a shortlist of finalists and then invite the public to vote for a winner on its Facebook page and website.
The competition is open to both small animal and equine vets, for the following systems:
Sarah O'Grady from BCF said: "Having a Cuattro DR system could make a huge difference to either a small animal or an equine practice. For a small animal vet practice that doesn't currently have a DR system, they will love the difference it makes to X-ray studies. Diagnostic images are produced in seconds and re-takes are almost non-existent. A Wireless Slate 3+ can greatly improve the ease of in-stable operations and procedures. With the removal of wires, these procedures run much smoother. You will also be surprised by the improvement in image quality."
The closing date for the competition is 30th November 2013.
To enter your video:
The winner will be required to arrange insurance for the system during the time they have the system. Full terms and conditions can be found on the BCF website.
To find out more visit the BCF website or Facebook page or call +44 (0)1506 460 023.
Academics from the University of Bristol's School of Veterinary Sciences and the neurology team at Southmead Hospital Bristol have published the results of study examining the use of percutaneous electrical nerve stimulation (PENS) therapy as a treatment for headshaking syndrome in horses.
The authors say that the condition, a neuropathic facial pain syndrome, often leaves affected horses impossible to ride and dangerous to handle, and can result in euthanasia. At present there are no consistently safe and effective methods for the treatment of headshaking in horses, and the condition is estimated to affect between 10,000 and 20,000 horses in the UK.
The study, which is published in the Equine Veterinary Journal (EVJ), aimed to discover whether PENS therapy, developed by Algotec Research and Development Ltd, is safe, effective and sustainable for the management of trigeminal-mediated headshaking in horses.
Seven horses diagnosed with trigeminal-mediated headshaking were recruited to the trial. All procedures were carried out in sedated horses with a needle-prick sized area of skin desensitised with local anaesthetic to help probe insertion. A disposable PENS probe was placed just beneath the skin adjacent to the nerve under ultrasonographic guidance. The nerve was stimulated for 25 minutes following a protocol of alternating frequencies and a perception threshold based on human clinical data. The probe was removed and the procedure repeated on the other side. Three or four treatments were used during the protocol, with treatments being repeated when signs of headshaking recurred.
All horses tolerated the procedure well. Three horses developed a haematoma at the site on one occasion and two had increased clinical signs for up to three days following first treatment. Six horses responded well after the first treatment and returned to ridden work at the same level before headshaking began. Five horses continued to respond to further treatment.
Veronica Roberts, Senior Clinical Fellow in Equine Medicine in the University's School of Veterinary Sciences, who led the study, said: "Headshaking in horses is a major welfare issue and can be a significant cause of distress.
"Although it is clear that further work is required, including increasing the number of cases and refining the treatment procedures, the study shows that PENS therapy should be the first-line treatment for trigeminal-mediated headshakers, which have failed to respond to conservative treatment, such as nose-nets."
Reference
The term ‘evidence synthesis’ describes a range of methodological approaches used to systematically review, appraise, and summarise evidence on a specific area.
The approaches differ from conventional literature reviews or narrative reviews, which are not required to have a specified search strategy or methodology for appraising evidence, and usually present a personal perspective or opinion.
There are three main types of evidence syntheses: rapid reviews, systematic reviews, and scoping reviews.
All have key principles in common, which includes the formulation of a structured question, a systematic search of the available literature, a defined process of reviewing and selecting suitable publications, and a methodology for analysing the final included evidence.
Evidence synthesis is still not widely used in the equine veterinary world, despite its recognised value in human evidence-based medicine.
In the new virtual collection, the EVJ discusses the what and the why of this important evaluation method, as well as providing free access to all the equine veterinary evidence reviews published to date, including:
“Evidence synthesis makes an important contribution towards generating the evidence base which underpins equine clinical practice,” said Professor Sarah Freeman. “The challenge compared to human medicine is that equine veterinary data sets are much smaller, and study approaches and methodologies often vary significantly which means that it may not be possible to combine or collate data sets.
“Given this shortfall, scoping reviews can be helpful to identify what information is out there, find areas where a systematic review could be performed, and provide a useful summary for all the studies in a particular area.”
Professor Celia Marr, Editor of the EVJ said: “As increasing numbers of evidence syntheses are published, they will expand our understanding of the current bodies of evidence in veterinary medicine.
“The existing studies are already informing us on how we use evidence in our practices and policies, and it is encouraging to anticipate how they will shape our development of future research, to generate the best evidence as the norm, in every case.”
The virtual issue can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.evidence-synthesis-collection
A new study published this month in the Equine Veterinary Journal (EVJ)1 has concluded that toxins from the seeds of the sycamore tree (Acer pseudoplatanus) are the likely cause of Atypical Myopathy (AM) in Europe.
However, to avoid confusion, the authors of the study point out that the American Sycamore (also just called 'the sycamore' in the USA), is a completely different species: Platanus occidentalis. Furthermore, the sycamore found in the UK is also known as the sycamore maple in other countries.
The new research follows on the heels of a study in the USA earlier this year that linked toxins from the box elder tree (Acer negundo) with Seasonal Pasture Myopathy (SPM), the US equivalent of AM2. The discovery marks an important step for the future prevention of this fatal disease.
Atypical Myopathy is a highly fatal muscle disease in the UK and Northern Europe. In ten years, approximately twenty European countries have reported the disease. Incidences tend to occur repeatedly in the autumn and in the spring following large autumnal outbreaks. Horses that develop AM are usually kept in sparse pastures with an accumulation of dead leaves, dead wood and trees in or around the pasture and are often not fed any supplementary hay or feed. SPM is a very similar disorder, prevalent in Midwestern USA and Eastern Canada that is now known to be caused by the ingestion of hypoglycin A, contained in seeds from the box elder tree.
The new European research1 was conducted by an international team led by Dominic Votion, University of Liege and involved 17 horses from Belgium, Germany and The Netherlands, suffering from Atypical Myopathy. High concentrations of a toxic metabolite of hypoglycin A, were identified in the serum of all of the horses. The pastures of 12 of the horses were visited by experienced botanists and the Acer pseudoplatanus, the sycamore maple, was found to be present in every case. This was the only tree common to all visited pastures.
Researchers believe hypoglycin A is the likely cause of both AM in Europe and SPM in North America. The sycamore and the box elder are known to produce seeds containing hypoglycin A and the pastures of the afflicted horses in Europe and the USA were surrounded by these trees.
Hypoglycin-A is found in various levels in the seeds of plants in the genus Acer as well as in various other genera in the family Sapindaceae such as ackee (Blighia sapida). In ackee, hypoglycin-A levels do vary with ripeness of the fruit and, if the fruit is eaten before it is mature, it causes hypoglycaemia to different degrees including a condition called "Jamaican vomiting sickness" (because of ackee's use in Jamaican cooking) and occasionally death in humans.
Researchers at the Universities of Minnesota2 and Liege are continuing their work to try to uncover exactly how the equine disease occurs. Dr Adrian Hegeman of University of Minnesota said: "It is likely that the most important contributing factors to horses becoming poisoned by hypoglycin-A are the availability of seed in the field combined with lack of other feeding options. The seeds from two species of maples (box elder and sycamore maples) that we have tested include significant quantities of hypoglycin-A.
"We know that seeds contain highly variable quantities from seed to seed, even within a single tree. We do not know yet how hypoglycin-A levels vary seasonally, nor do we know how its abundance varies with different levels of stress to the plant, though this may well explain seasonal variability in the occurrence of the malady. It is possible that conditions that stress the plants may contribute to significant seasonal changes in hypoglycin-A levels. At this point we just don't know. It is common held knowledge that trees under stress usually produce more seed."
Dr Jeff Gillman of University of Minnesota said: "Without question, further analysis of the seeds and other tissues from Acer species needs to be performed along with sampling of plant materials over multiple seasons and at various stress levels. Additionally, one cannot rule out more complex explanations for the seasonality of disease occurrence such as: animals may begin feeding on seed materials in response to depletion of more palatable choices under drought conditions; or simple explanations such as high wind events driving seeds into fields. These sorts of explanations for the occurrence of the disease do not depend on botanical variations in toxicity across seasons, sites or stress levels, yet also require consideration.
"Although limited examples are available, the experience of animals at a pasture site might also confer some degree of behavioral resistance to poisoning due to exposure at sub-lethal levels with prior exposure to seeds in the pasture."
Professor Celia Marr, Editor of Equine Veterinary Journal said: "This is an important advancement in our understanding of what causes AM and how it can be prevented. In immediate practical terms owners can take prompt measures to avoid exposing their horses to sycamore seeds this autumn. Where horses are grazing in the vicinity of sycamore trees, it is imperative that they are provided with sufficient supplementary feed as this will minimise the risk that horses might be tempted to ingest seeds containing this toxin. This must be done carefully and leaving wet hay on the ground should be avoided so providing extra carbohydrate feeds may be more practical."
Invicta Animal Health has announced that that EquiChek test kits are now validated for use with synovial fluid, having originally been validated for whole blood only.
EquiChek is an animal-side test to assess the level of Serum Amyloid A (SAA) which is a major acute phase protein of inflammation in horses.
Invicta says that it has been shown that SAA levels in synovial fluid are not influenced by arthrocentesis*, which makes SAA an ideal biomarker to measure whilst monitoring or assessing joint function.
The company says this is the first test which is able to provide a visual semi-quantitative result within 15 minutes. The test will display 4 lines for a normal level of SAA and sequentially fewer lines depending on the severity of the inflammation.
Rob Watkins, Managing Director of Invicta, said: "EquiChek has proved to be a useful tool in the ambulatory toolkit. The validation of synovial fluid extends the use by allowing real-time monitoring of lameness and intra-articular therapies. Normally whilst medicating joints, excess synovial fluid is discarded. Now this can be utilised to assist diagnosis or to assess the response to medication."
Invicta will be at Stand A16 BEVA Congress 2013.
For further information see www.invictavet.com/ or ring 01403 791313
Last year BEVA received a national Antibiotic Guardian award from Public Health England in recognition of its work to promote responsible use of antibiotics. It was the only organisation from the veterinary profession to be shortlisted. BEVA launched its Protect ME antimicrobial campaign in 2012 to coincide with European Antimicrobial Awareness day. The Association has launched additional resources each year to facilitate compliance and educate the public about the importance of antimicrobial awareness.
This year, to recognise World Antibiotic Awareness Week (16th to 22nd November, 2016) and European Antibiotic Awareness Day (18th November), BEVA is encouraging members to document their efforts to reduce the use of critically important antibiotics.
To enter for the award, veterinary surgeons need to share practice sales data (in mls) of chosen antibiotics. Practices that document a reduction in antibiotic sales of these drugs will be presented with a BEVA Antibiotic Champion Award to endorse their commitment to responsible use of antibiotics and to help promote public awareness of the campaign. Members are also encouraged to sign up to be antibiotic guardians at www.antibioticguardian.com
Gayle Hallowell, Co-Chair of the BEVA Health and Medicines Committee said: "We are extremely proud of the equine veterinary profession’s commitment to the responsible use of antibiotics. We hope the introduction of our Champion Award will inject new vigour into efforts to continue to reduce the use of our precariously limited antibiotic resources."
To apply for BEVA Antibiotic Champion Award status visit http://www.beva.org.uk/Antibiotic-Champion-Award The BEVA Protect ME toolkit is free to BEVA members and can be downloaded at www.beva.org.uk.